MEI Pharma (MEIP) Stock Forecast, Price Target & Predictions

MEIP Stock Forecast

MEI Pharma stock forecast is as follows: a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.

MEIP Analyst Ratings

Hold

According to 3 Wall Street analysts, MEI Pharma's rating consensus is 'Hold'. The analyst rating breakdown for MEIP stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 23, 2024	Laidlaw	-	Hold	Downgrade
Jul 22, 2024	Brookline Capital	Buy	Hold	Downgrade
Feb 08, 2023	Jefferies	-	Underperform	Downgrade
Dec 06, 2022	BTIG	-	Neutral	Downgrade
Apr 12, 2022	Brookline Capital	Buy	Buy	Hold

Row per page

Go to

MEI Pharma's last stock rating was published by Laidlaw on Jul 23, 2024. The company Downgrade its MEIP rating from "null" to "Hold".

MEI Pharma Financial Forecast

MEI Pharma Revenue Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 08	Mar 07	Mar 06	Mar 05	Mar 04
Revenue	-	-	-	-	-	-	$5.89M	$32.73M	$8.73M	$11.41M	$9.69M	$18.22M	$13.39M	$10.12M	$2.42M	$9.17M	$3.83M	$25.50M	$1.24M	$1.01M	$1.16M	$1.13M	$1.25M	$433.00K	$4.50M	-	-	-	-	-
Avg Forecast	-	-	$50.00K	$37.50K	$100.00K	$620.67K	$346.75K	$4.42M	$4.42M	$4.78M	$3.44M	$5.26M	$10.56M	$4.17M	$5.41M	$2.92M	$3.67M	$45.07M	$1.58M	$1.58M	$1.33M	$715.86K	$690.71K	$645.00K	$9.02M	$440.40K	$456.00K	$83.33K	$93.33K	$53.33K
High Forecast	-	-	$50.00K	$37.75K	$100.00K	$620.67K	$346.75K	$4.42M	$4.42M	$4.78M	$3.44M	$5.26M	$10.56M	$4.17M	$5.41M	$2.92M	$3.67M	$45.07M	$1.58M	$1.58M	$1.33M	$715.86K	$690.71K	$774.00K	$10.82M	$528.48K	$547.20K	$100.00K	$112.00K	$64.00K
Low Forecast	-	-	$50.00K	$37.25K	$100.00K	$620.67K	$346.75K	$4.42M	$4.42M	$4.78M	$3.44M	$5.26M	$10.56M	$4.17M	$5.41M	$2.92M	$3.67M	$45.07M	$1.58M	$1.58M	$1.33M	$715.86K	$690.71K	$516.00K	$7.22M	$352.32K	$364.80K	$66.67K	$74.67K	$42.66K
# Analysts	-	-	1	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	16	12	14	9	16	11
Surprise %	-	-	-	-	-	-	17.00%	7.41%	1.98%	2.39%	2.82%	3.46%	1.27%	2.43%	0.45%	3.14%	1.05%	0.57%	0.79%	0.64%	0.87%	1.58%	1.81%	0.67%	0.50%	-	-	-	-	-

MEI Pharma's average Quarter revenue forecast for Jun 23 based on 1 analysts is $620.67K, with a low forecast of $620.67K, and a high forecast of $620.67K. MEIP's average Quarter revenue forecast represents a -89.47% decrease compared to the company's last Quarter revenue of $5.89M (Mar 23).

MEI Pharma EBITDA Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 08	Mar 07	Mar 06	Mar 05	Mar 04
# Analysts	-	-	1	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	16	12	14	9	16	11
EBITDA	-	-	-	-	$-11.93M	-	$-16.29M	$8.53M	$-19.24M	$-16.04M	$-34.33M	$-5.69M	$-11.80M	$-5.65M	$-31.24M	$-11.38M	$-2.02M	$-18.46M	$-4.30M	$-20.19M	$-2.96M	$3.08M	$-17.33M	$-5.93M	$-589.00K	-	-	-	-	-
Avg Forecast	-	-	$-32.34K	$-10.95M	$-64.68K	$-401.46K	$-11.71M	$-7.00M	$-2.01M	$-2.17M	$-12.52M	$-2.39M	$-4.80M	$-1.89M	$-28.82M	$-1.32M	$-1.67M	$-20.46M	$-6.63M	$-715.84K	$-603.34K	$-324.95K	$-11.21M	$-7.91M	$-795.15K	$-3.89M	$-2.52M	$-2.60M	$-2.17M	$-847.55K
High Forecast	-	-	$-32.34K	$-8.76M	$-64.68K	$-401.46K	$-9.37M	$-5.60M	$-2.01M	$-2.17M	$-10.02M	$-2.39M	$-4.80M	$-1.89M	$-23.06M	$-1.32M	$-1.67M	$-20.46M	$-5.31M	$-715.84K	$-603.34K	$-324.95K	$-8.97M	$-6.33M	$-636.12K	$-3.11M	$-2.01M	$-2.08M	$-1.74M	$-678.04K
Low Forecast	-	-	$-32.34K	$-13.14M	$-64.68K	$-401.46K	$-14.05M	$-8.40M	$-2.01M	$-2.17M	$-15.03M	$-2.39M	$-4.80M	$-1.89M	$-34.59M	$-1.32M	$-1.67M	$-20.46M	$-7.96M	$-715.84K	$-603.34K	$-324.95K	$-13.46M	$-9.50M	$-954.18K	$-4.66M	$-3.02M	$-3.12M	$-2.61M	$-1.02M
Surprise %	-	-	-	-	184.44%	-	1.39%	-1.22%	9.59%	7.40%	2.74%	2.38%	2.46%	2.98%	1.08%	8.60%	1.21%	0.90%	0.65%	28.20%	4.91%	-9.48%	1.55%	0.75%	0.74%	-	-	-	-	-

1 analysts predict MEIP's average Quarter EBITDA for Mar 23 to be $-11.71M, with a high of $-9.37M and a low of $-14.05M. This is -237.23% lower than MEI Pharma's previous annual EBITDA (Dec 22) of $8.53M.

MEI Pharma Net Income Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 08	Mar 07	Mar 06	Mar 05	Mar 04
# Analysts	-	-	1	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	16	12	14	9	16	11
Net Income	-	-	-	-	$-11.06M	-	$-14.48M	$10.25M	$-17.10M	$-16.27M	$16.97M	$-5.77M	$-11.88M	$-5.72M	$-31.31M	$-11.45M	$-2.09M	$-18.48M	$-4.33M	$-20.22M	$-2.99M	$3.05M	$-17.36M	$-5.95M	$-602.00K	-	-	-	-	-
Avg Forecast	$-14.66M	$-11.33M	$-9.37M	$-11.06M	$-9.42M	$-18.63M	$-11.83M	$-7.09M	$-22.31M	$-25.64M	$-12.65M	$-25.16M	$-17.51M	$-22.45M	$-28.89M	$-17.54M	$-10.92M	$28.64M	$-6.68M	$-21.84M	$-21.98M	$-25.88M	$-11.23M	$-7.93M	$-812.70K	$-3.89M	$-2.52M	$-2.60M	$-2.17M	$-847.55K
High Forecast	$-14.66M	$-11.33M	$-9.37M	$-8.85M	$-8.58M	$-18.63M	$-9.46M	$-5.67M	$-22.31M	$-25.64M	$-10.12M	$-25.16M	$-17.51M	$-22.45M	$-23.11M	$-17.54M	$-10.92M	$28.64M	$-5.34M	$-21.84M	$-21.98M	$-25.88M	$-8.98M	$-6.34M	$-650.16K	$-3.11M	$-2.02M	$-2.08M	$-1.74M	$-678.04K
Low Forecast	$-14.66M	$-11.33M	$-9.37M	$-13.27M	$-10.26M	$-18.63M	$-14.19M	$-8.51M	$-22.31M	$-25.64M	$-15.18M	$-25.16M	$-17.51M	$-22.45M	$-34.67M	$-17.54M	$-10.92M	$28.64M	$-8.01M	$-21.84M	$-21.98M	$-25.88M	$-13.48M	$-9.52M	$-975.24K	$-4.66M	$-3.02M	$-3.12M	$-2.61M	$-1.02M
Surprise %	-	-	-	-	1.17%	-	1.22%	-1.45%	0.77%	0.63%	-1.34%	0.23%	0.68%	0.25%	1.08%	0.65%	0.19%	-0.65%	0.65%	0.93%	0.14%	-0.12%	1.55%	0.75%	0.74%	-	-	-	-	-

MEI Pharma's average Quarter net income forecast for Mar 23 is $-11.83M, with a range of $-14.19M to $-9.46M. MEIP's average Quarter net income forecast represents a -215.37% decrease compared to the company's last Quarter net income of $10.25M (Dec 22).

MEI Pharma SG&A Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 08	Mar 07	Mar 06	Mar 05	Mar 04
# Analysts	-	-	1	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	16	12	14	9	16	11
SG&A	-	-	-	-	$8.02M	-	$7.18M	$8.50M	$7.49M	$5.77M	$8.93M	$7.93M	$7.91M	$6.63M	$6.21M	$5.65M	$5.92M	$4.53M	$3.86M	$4.20M	$4.13M	$3.74M	$3.63M	$2.49M	$2.15M	-	-	-	-	-
Avg Forecast	-	-	$33.20K	$24.90K	$66.40K	$412.14K	$230.25K	$2.93M	$2.93M	$3.17M	$2.28M	$3.49M	$7.01M	$2.77M	$3.59M	$1.94M	$2.44M	$29.93M	$1.05M	$1.05M	$882.60K	$475.35K	$458.65K	$428.30K	$2.91M	$292.44K	$302.80K	$55.34K	$61.98K	$35.41K
High Forecast	-	-	$33.20K	$25.07K	$66.40K	$412.14K	$230.25K	$2.93M	$2.93M	$3.17M	$2.28M	$3.49M	$7.01M	$2.77M	$3.59M	$1.94M	$2.44M	$29.93M	$1.05M	$1.05M	$882.60K	$475.35K	$458.65K	$513.96K	$3.49M	$350.92K	$363.36K	$66.40K	$74.37K	$42.50K
Low Forecast	-	-	$33.20K	$24.73K	$66.40K	$412.14K	$230.25K	$2.93M	$2.93M	$3.17M	$2.28M	$3.49M	$7.01M	$2.77M	$3.59M	$1.94M	$2.44M	$29.93M	$1.05M	$1.05M	$882.60K	$475.35K	$458.65K	$342.64K	$2.32M	$233.95K	$242.24K	$44.27K	$49.58K	$28.33K
Surprise %	-	-	-	-	120.75%	-	31.19%	2.90%	2.55%	1.82%	3.91%	2.27%	1.13%	2.40%	1.73%	2.92%	2.43%	0.15%	3.69%	4.01%	4.68%	7.88%	7.92%	5.80%	0.74%	-	-	-	-	-

MEI Pharma's average Quarter SG&A projection for Mar 24 is $24.90K, based on 1 Wall Street analysts, with a range of $24.73K to $25.07K. The forecast indicates a -99.69% fall compared to MEIP last annual SG&A of $8.02M (Dec 23).

MEI Pharma EPS Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 08	Mar 07	Mar 06	Mar 05	Mar 04
# Analysts	-	-	1	1	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	16	12	14	9	16	11
EPS	-	-	-	-	$-1.66	-	$-2.17	$0.08	$-0.13	$-0.13	$0.13	$-0.05	$-0.11	$-0.05	$-0.28	$-0.10	$-0.02	$-0.16	$-0.04	$-0.26	$-0.04	$0.04	$-0.24	$-0.16	$-0.02	-	-	-	-	-
Avg Forecast	$-2.20	$-1.70	$-1.41	$-1.49	$-1.41	$-2.80	$-2.90	$-3.03	$-3.35	$-3.85	$-3.67	$-3.78	$-2.63	$-3.37	$-3.12	$-2.63	$-1.64	$4.30	$-2.60	$-3.28	$-3.30	$-3.89	$-3.37	$-0.32	$-0.05	$-4.20	$-7.02	$-2.40	$-3.00	$-0.66
High Forecast	$-2.20	$-1.70	$-1.41	$-1.49	$-1.29	$-2.80	$-2.90	$-3.03	$-3.35	$-3.85	$-3.67	$-3.78	$-2.63	$-3.37	$-3.12	$-2.63	$-1.64	$4.30	$-2.60	$-3.28	$-3.30	$-3.89	$-3.37	$-0.26	$-0.04	$-3.36	$-5.62	$-1.92	$-2.40	$-0.53
Low Forecast	$-2.20	$-1.70	$-1.41	$-1.49	$-1.54	$-2.80	$-2.90	$-3.03	$-3.35	$-3.85	$-3.67	$-3.78	$-2.63	$-3.37	$-3.12	$-2.63	$-1.64	$4.30	$-2.60	$-3.28	$-3.30	$-3.89	$-3.37	$-0.38	$-0.06	$-5.04	$-8.42	$-2.88	$-3.60	$-0.79
Surprise %	-	-	-	-	1.17%	-	0.75%	-0.03%	0.04%	0.03%	-0.04%	0.01%	0.04%	0.02%	0.09%	0.04%	0.01%	-0.04%	0.02%	0.08%	0.01%	-0.01%	0.07%	0.50%	0.40%	-	-	-	-	-

According to 1 Wall Street analysts, MEI Pharma's projected average Quarter EPS for Mar 23 is $-2.90, with a low estimate of $-2.90 and a high estimate of $-2.90. This represents a -3725.00% decrease compared to MEIP previous annual EPS of $0.08 (Dec 22).

MEI Pharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VINC	Vincerx Pharma	$0.26	$3.00	1053.85%	Buy
SPRO	Spero Therapeutics	$1.19	$10.00	740.34%	Buy
CTMX	CytomX Therapeutics	$0.87	$5.73	558.62%	Buy
ATXI	Avenue Therapeutics	$2.01	$12.00	497.01%	Buy
INZY	Inozyme Pharma	$2.69	$14.67	445.35%	Buy
MEIP	MEI Pharma	$2.81	$15.00	433.81%	Buy
ZURA	Zura Bio	$2.93	$10.00	241.30%	Buy
TIL	Instil Bio	$24.76	$78.25	216.03%	Hold
ABOS	Acumen Pharmaceuticals	$2.31	$7.00	203.03%	Buy
DAWN	Day One Biopharmaceuticals	$13.34	$38.80	190.85%	Buy
TERN	Terns Pharmaceuticals	$5.71	$14.25	149.56%	Buy
ASMB	Assembly Biosciences	$14.72	$35.50	141.17%	Buy
KZR	Kezar Life Sciences	$7.62	$17.50	129.66%	Buy
OCUL	Ocular Therapeutix	$8.52	$17.50	105.40%	Buy
ACHL	Achilles Therapeutics	$1.07	$2.00	86.92%	Buy
HOOK	HOOKIPA Pharma	$2.30	$3.00	30.43%	Buy

MEIP Forecast FAQ

Is MEI Pharma a good buy?

No, according to 3 Wall Street analysts, MEI Pharma (MEIP) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of MEIP's total ratings.

What are MEI Pharma's analysts' financial forecasts?

MEI Pharma's analysts financial forecasts for the fiscal year (Jun 2023) are as follows: average revenue is $9.8M (high $9.8M, low $9.8M), average EBITDA is $-21.117M (high $-17.375M, low $-24.859M), average net income is $-59.868M (high $-56.083M, low $-63.652M), average SG&A $6.51M (high $6.51M, low $6.51M), and average EPS is $-12.08 (high $-12.08, low $-12.08). MEIP's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $187.5K (high $187.75K, low $187.25K), average EBITDA is $-11.044M (high $-8.855M, low $-13.234M), average net income is $-29.85M (high $-26.799M, low $-32.9M), average SG&A $124.5K (high $124.67K, low $124.34K), and average EPS is $-4.307 (high $-4.181, low $-4.433).

Did the MEIP's actual financial results beat the analysts' financial forecasts?

Based on MEI Pharma's last annual report (Jun 2022), the company's revenue was $40.7M, beating the average analysts forecast of $24.04M by 69.28%. Apple's EBITDA was $-95.91M, beating the average prediction of $-21.874M by 338.46%. The company's net income was $-54.738M, missing the average estimation of $-80.962M by -32.39%. Apple's SG&A was $30.54M, beating the average forecast of $15.96M by 91.31%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-13.928 by -96.84%. In terms of the last quarterly report (Mar 2023), MEI Pharma's revenue was $5.89M, beating the average analysts' forecast of $346.75K by 1599.78%. The company's EBITDA was $-16.294M, beating the average prediction of $-11.708M by 39.17%. MEI Pharma's net income was $-14.485M, beating the average estimation of $-11.829M by 22.45%. The company's SG&A was $7.18M, beating the average forecast of $230.25K by 3018.77%. Lastly, the company's EPS was $-2.17, missing the average prediction of $-2.9 by -25.17%